DEG6498 for people with advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a first-in-human, multi-center, open-label Phase 1 trial with two parts: a dose-escalation phase to determine the maximum tolerated dose and recommended Phase 2 dose, followed by a dose-expansion phase focusing on BRAF-mutant tumors and hepatocellular carcinoma (HCC). Participants will take DEG6498 orally once a day and undergo regular safety monitoring, blood sampling for pharmacokinetics (PK), and tumor assessments. The study will record adverse events, dose-limiting toxicities, and any tumor responses to characterize safety and preliminary efficacy. Data from both parts will guide dose selection and further clinical development.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Willing and able to provide written informed consent for the study prior to the performance of any study-specific procedures
2. Male and female older than or equal to 18 years of age at the time signing the informed consent form (ICF)
3. If female, must be postmenopausal, or surgically sterile, or agree to highly effective contraceptive measures to prevent pregnancy throughout treatment period and within 30 days of last study drug treatment
4. Women of childbearing potential (WOCBP) must have 2 negative pregnancy tests (1 serum test required) as verified by the investigator prior to starting study drug
5. If male, must agree to inform and ensure their female partners to use highly effective contraception measures to prevent pregnancy, and to refrain from donating sperm while on study drug and for at least 30 days following DEG6498 discontinuation
6. Patients with advanced solid tumors, who have failed standard therapies, or for whom no standard therapy exists

   1. Part 1: Advanced solid tumor patients
   2. Part 2: Patients with BRAF mutation positive tumors and HCC
7. Presence of at least 1 measurable lesion according to RECIST v1.1 .
8. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

1. Participant has a significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study, puts the participant at unacceptable risk if he/she were to participate in the study
2. Participant has a condition that confounds the ability for interpret data from the study
3. Pregnant or breastfeeding women
4. Active or concurrent malignancy requiring treatment (including both systemic therapy and radiotherapy) within 14 days or 5 half lives (whichever is shorter) prior to the first dose of study drug, or received antibody therapy within 28 days
5. Symptomatic CNS metastases which are neurologically unstable, or CNS metastases requiring local CNS directed therapy, or increasing doses of corticosteroids within 2 weeks of first dose of study treatment.
6. Clinically significant cardiovascular disease
7. Known active or chronic infection that requires systemic therapy within 2 weeks of first dose of study drug
8. Known human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome, or active HBV or HCV infection.

Where it's running

• Beijing Cancer Hospital
  Beijing, Beijing Municipality, China Recruiting
• Beijing GoBroad Hospital
  Beijing, Beijing Municipality, China Recruiting
• Sun Yat-Sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Degron Therapeutics Co.
• Email: clinicaltrials@degrontx.com
• Phone: +86-21-60799565

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• YKYY031 injection in advanced solid tumors in adults

  A phase 1 trial tests YKYY031 given by injection in adults with advanced solid tumors who have few other treatment options to see if it is safe and how it behaves in the body.

  Recruiting Phase 1 Youcare Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07631793

• SLC-3010 plus axitinib versus axitinib alone for second-line treatment of advanced clear cell kidney cancer

  This trial tests whether adding SLC-3010 to axitinib works better than axitinib alone for adults with locally advanced or metastatic clear cell kidney cancer who need second-line treatment.

  Recruiting Phase 2 Yonsei University · Seoul · NCT07469683

• Extension program for people previously treated with belzutifan (MK-6482)

  This extension lets people with advanced solid tumors or VHL-related tumors who were already taking belzutifan in another study continue the drug so researchers can see how long they live and watch for long-term effects.

  Recruiting at 50 sites Phase 3 Merck Sharp & Dohme LLC · Boston, Massachusetts and 56 other locations · NCT07405164

• Understanding sexual side effects after radiotherapy in female cancer patients

  This study is trying to understand how radiotherapy and other cancer treatments affect sexual health in women with cancer to help improve their quality of life.

  Recruiting at 3 sites Icahn School of Medicine at Mount Sinai · Atlanta, Georgia and 2 other locations · NCT05394428

• Collection of blood and tissue samples from patients with suspected or confirmed cancer

  This study is collecting blood and tissue samples from patients with suspected or confirmed cancer to help researchers learn more about how these cancers develop and find new treatment options.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT00026884

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.